Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Olema Pharmaceuticals, Inc. (OLMA : NSDQ)
 
 • Company Description   
Olema Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It engages in discovery, development and commercialization of therapies for women's cancers. The company's product pipeline includes OP-1250, which is in clinical stage. Olema Pharmaceuticals Inc. is based in San Francisco, California.

Number of Employees: 74

 
 • Price / Volume Information   
Yesterday's Closing Price: $2.26 Daily Weekly Monthly
20 Day Moving Average: 340,231 shares
Shares Outstanding: 40.35 (millions)
Market Capitalization: $91.20 (millions)
Beta: 2.54
52 Week High: $32.77
52 Week Low: $2.00
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -23.65% -14.01%
12 Week -49.21% -44.17%
Year To Date -75.85% -69.98%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
512 2nd Street 4th Floor
-
San Francisco,CA 94107
USA
ph: 650-243-5555
fax: -
ir@olema.com http://www.olema.com
 
 • General Corporate Information   
Officers
Sean Bohen - President and Chief Executive Officer
Shane Kovacs - Chief Operating and Financial Officer
Ian Clark - Director
Cynthia Butitta - Director
Cyrus L. Harmon - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 68062P106
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/09/22
Share - Related Items
Shares Outstanding: 40.35
Most Recent Split Date: (:1)
Beta: 2.54
Market Capitalization: $91.20 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.65 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-2.87 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/09/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 0.34
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -48.72%
vs. Previous Quarter: -7.41%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -27.06
12/31/21 - -23.20
09/30/21 - -18.63
ROA
03/31/22 - -26.15
12/31/21 - -22.58
09/30/21 - -18.25
Current Ratio
03/31/22 - 26.58
12/31/21 - 32.23
09/30/21 - 34.63
Quick Ratio
03/31/22 - 26.57
12/31/21 - 32.23
09/30/21 - 34.63
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 6.57
12/31/21 - 7.06
09/30/21 - 7.61
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©